Show simple item record

dc.contributor.authorRangaka, M X
dc.contributor.authorWilkinson, R J
dc.contributor.authorBoulle, A
dc.contributor.authorGlynn, J R
dc.contributor.authorFielding, K
dc.contributor.authorvan Cutsem, G
dc.contributor.authorWilkinson, K A
dc.contributor.authorGoliath, R
dc.contributor.authorMathee, S
dc.contributor.authorGoemaere, E
dc.contributor.authorMaartens, G
dc.date.accessioned2014-07-03T22:34:34Z
dc.date.available2014-07-03T22:34:34Z
dc.date.issued2014-05-13
dc.identifier.citationIsoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial. 2014: Lanceten_GB
dc.identifier.issn1474-547X
dc.identifier.pmid24835842
dc.identifier.doi10.1016/S0140-6736(14)60162-8
dc.identifier.urihttp://hdl.handle.net/10144/322390
dc.description.abstractAntiretroviral therapy reduces the risk of tuberculosis, but tuberculosis is more common in people with HIV than in people without HIV. We aimed to assess the effect of isoniazid preventive therapy on the risk of tuberculosis in people infected with HIV-1 concurrently receiving antiretroviral therapy.
dc.languageENG
dc.language.isoenen
dc.publisherThe Lanceten_GB
dc.rightsReproduced on this site with permission of Elsevier Ltd. Please see [url]http://www.thelancet.com/[/url] for further relevant comment.en_GB
dc.titleIsoniazid plus antiretroviral therapy to prevent tuberculosis: a randomised double-blind, placebo-controlled trial.en
dc.identifier.journalLanceten_GB
refterms.dateFOA2019-03-04T11:15:55Z
html.description.abstractAntiretroviral therapy reduces the risk of tuberculosis, but tuberculosis is more common in people with HIV than in people without HIV. We aimed to assess the effect of isoniazid preventive therapy on the risk of tuberculosis in people infected with HIV-1 concurrently receiving antiretroviral therapy.


Files in this item

Thumbnail
Name:
Rangaka MX-2014-Isoniazid plus ...
Size:
603.2Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record